Elicio Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Elicio Therapeutics, Inc. (ELTX) on March 21, 2025. The filing discloses the appointment of a new senior executive officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Appointment: Preetam Shah, Ph.D., M.B.A., was appointed as Chief Strategy and Financial Officer, effective March 24, 2025.
- Role Expansion: Effective April 1, 2025, Dr. Shah will also serve as the Company's Principal Financial Officer and Principal Accounting Officer.
- Compensation Structure:
- Annual base salary: $480,000.
- Target annual performance bonus: 40% of base salary.
- Initial Option Grant: Equal to 1.2% of total common stock outstanding as of April 15, 2025.
- Vesting Schedule: 25% on the first anniversary of the start date, with the remainder vesting in 36 equal monthly installments.
Outlook, Risks, and Management Commentary
Dr. Shah brings significant experience from Cidara Therapeutics, Inc., Brainstorm Cell Therapeutics, Inc., and investment banking roles at Barclays Capital and Canaccord Genuity. The filing states there are no undisclosed arrangements or related party transactions involving Dr. Shah. The Company has entered into an Executive Severance Plan for Dr. Shah.
Investor Verification Checklist
- Verify the exact number of shares outstanding as of April 15, 2025, to calculate the specific share count of the Initial Option Grant.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific performance goals tied to the bonus and severance terms.
- Confirm the transition timeline for Dr. Shah assuming the roles of Principal Financial Officer and Principal Accounting Officer on April 1, 2025.
- Check subsequent filings for any changes to the Company's capital structure that might affect the 1.2% option grant calculation.